➤ Subscribe for Complete Access

Flexible subscription options to meet your unique needs…

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Dow
Mallinckrodt
McKesson
Colorcon

Last Updated: November 27, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TRIFAROTENE

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Trifarotene

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02189629 ↗ CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris Completed Galderma R&D Phase 3 2015-02-23 Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris.
NCT02556788 ↗ Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris Completed Galderma R&D Phase 3 2015-11-01 Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
NCT02566369 ↗ Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris Completed Galderma R&D Phase 3 2015-11-30 Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
NCT03738800 ↗ A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis Terminated Mayne Pharma International Pty Ltd Phase 2 2019-05-01 This is a phase 2 randomized, multi-center, double-blind, vehicle controlled, 90 day, safety, efficacy, and systemic exposure study followed by a 90 day open-label extension of trifarotene cream in adults and adolescents with autosomal recessive ichthyosis with lamellar scale.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Trifarotene

Condition Name

Condition Name for Trifarotene
Intervention Trials
Acne Vulgaris 7
Lamellar Ichthyosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Trifarotene
Intervention Trials
Acne Vulgaris 7
Ichthyosis, Lamellar 1
Ichthyosis 1
Hyperpigmentation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Trifarotene

Trials by Country

Trials by Country for Trifarotene
Location Trials
United States 101
Canada 7
Hungary 3
Germany 3
Czechia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Trifarotene
Location Trials
Texas 7
California 7
Arkansas 6
Pennsylvania 6
New York 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Trifarotene

Clinical Trial Phase

Clinical Trial Phase for Trifarotene
Clinical Trial Phase Trials
Phase 4 3
Phase 3 4
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Trifarotene
Clinical Trial Phase Trials
Completed 5
Recruiting 1
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Trifarotene

Sponsor Name

Sponsor Name for Trifarotene
Sponsor Trials
Galderma R&D 7
Mayne Pharma International Pty Ltd 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Trifarotene
Sponsor Trials
Industry 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Johnson and Johnson
Merck
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.